Multicenter open-label sertraline study in adolescent outpatients with major depression

Paul J. Ambrosini, Karen Dineen Wagner, Joseph Biederman, Ira Click, Claire Tan, Josephine Elia, Joan R. Hebeler, Harris Rabinovich, James Lock, Daniel Geller

Research output: Contribution to journalArticle

84 Scopus citations

Abstract

Objective: The aim of this multicenter outpatient study was to assess the therapeutic benefits, response patterns, and safety of sertraline in adolescent major depressive disorder (MDD). Method: Fifty-three adolescent outpatients with MDD were treated in an open-label, 10-week, acute-phase trial with sertraline and, if responders, for an additional 12-week continuation phase. Diagnostic and response assessments included the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), 17-item K-SADS-derived depression severity score, Hamilton Depression Rating Scale, Beck Depression Inventory, and Clinical Global Impression Scale. Results: By 2 weeks, when analyzed as continuous variables, all severity scores showed significant differences from baseline. This pattern persisted through 10 weeks, with a significantly greater response occurring when treatment was extended from 6 to 10 weeks. Both clinician- and patient-rated improvement was maintained during continuation treatment. Response rates varied considerably when depression rating scales were analyzed categorically. Sertraline was generally well tolerated and did not induce manic symptoms. Conclusions: In open treatment of adolescent MDD with sertraline, significant improvement occurred early on and was maintained for 22 weeks. Absolute response rates varied depending on the rating scales used, definition of response, and length of treatment. Maximal response rates were obtained by clinician-defined ratings after 10 weeks of treatment.

Original languageEnglish (US)
Pages (from-to)566-572
Number of pages7
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume38
Issue number5
DOIs
StatePublished - Jan 1 1999

Keywords

  • Adolescent
  • Depression
  • Pharmacotherapy
  • Rating scales
  • Sertraline

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Multicenter open-label sertraline study in adolescent outpatients with major depression'. Together they form a unique fingerprint.

  • Cite this

    Ambrosini, P. J., Wagner, K. D., Biederman, J., Click, I., Tan, C., Elia, J., Hebeler, J. R., Rabinovich, H., Lock, J., & Geller, D. (1999). Multicenter open-label sertraline study in adolescent outpatients with major depression. Journal of the American Academy of Child and Adolescent Psychiatry, 38(5), 566-572. https://doi.org/10.1097/00004583-199905000-00018